| 臺大學術典藏 |
2021-09-02T00:03:54Z |
First vertically stacked GeSn nanowire pGAAFETs with Ion = 1850μA/μm (VOV = VDS = -1V) on Si by GeSn/Ge CVD epitaxial growth and optimum selective etching
|
Huang Y.-S;Lu F.-L;Tsou Y.-J;Tsai C.-E;Lin C.-Y;Huang C.-H;Liu C.W.; Huang Y.-S; Lu F.-L; Tsou Y.-J; Tsai C.-E; Lin C.-Y; Huang C.-H; Liu C.W.; CHEE-WEE LIU |
| 臺大學術典藏 |
2021-09-02T00:03:54Z |
First Vertically Stacked Tensily Strained Ge0.98Si0.02 nGAAFETs with No Parasitic Channel and LG = 40 nm Featuring Record ION = 48 μa at VOV=VDS=0.5V and Record Gm,max(μS/μm)/SSSAT(mV/dec) = 8.3 at VDS=0.5V
|
Tu C.-T;Huang Y.-S;Lu F.-L;Liu H.-H;Lin C.-Y;Liu Y.-C;Liu C.W.; Tu C.-T; Huang Y.-S; Lu F.-L; Liu H.-H; Lin C.-Y; Liu Y.-C; Liu C.W.; CHEE-WEE LIU |
| 臺大學術典藏 |
2021-09-02T00:03:50Z |
Biaxial strain effects on photoluminescence of Ge/strained GeSn/Ge quantum well
|
Lin C.-Y;Ye H.-Y;Lu F.-L;Lan H.S;Liu C.W.; Lin C.-Y; Ye H.-Y; Lu F.-L; Lan H.S; Liu C.W.; CHEE-WEE LIU |
| 臺大學術典藏 |
2021-09-01T01:53:51Z |
Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma
|
Shen Y.-C.; Ou D.-L.; Hsu C.; Lin K.-L.; Chang C.-Y.; Lin C.-Y.; Liu S.-H.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-31T06:29:29Z |
Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Lu S.-N.; Wang J.-H.; Su C.-W.; Wang T.-E.; Dai C.-Y.; Chen C.-H.; Chen R.-C.; Yang S.-S.; Hung C.-F.; Huang S.-F.; Liao L.-Y.; Huo T.-I.; Wu C.-C.; Lee P.-H.; Ting C.-T.; Lee W.-C.; Chau G.-Y.; Wang C.-C.; Lee K.-T.; Huang Y.-H.; Ho M.-C.; Lin S.-M.; Huang G.-T.; Chen K.-Y.; Lin X.-Z.; Hwang J.-I.; Chiou Y.-Y.; Wang C.-K.; Hu J.-T.; Chen S.-C.; Liang P.-C.; Lee R.-C.; Wu D.-K.; Lin C.-Y.; Lin C.-C.; ANN-LII CHENG; Hsu C.; Chao Y.; Chen L.-T.; Wang P.-M.; Wang P.-M.; Hong J.-H.; Hsu H.-C.; Chen S.-W.; Leung S.W.; Cheng J.C.-H.; Wu J.-C.; Wu C.-Y.; Hsu Y.-C.; Hsu C.-W.; Ni Y.-H.; Lin C.-L.; Local ablation group, Surveillance group, Diagnosis group, Staging group, Surgery group, TACE/TARE/HAI group, Target therapy/systemic therapy group, Radiotherapy group, Prevention group, Drafting group |
| 臺大學術典藏 |
2021-08-31T05:35:44Z |
Risk-taking of bank CEOs and corporate innovation
|
Giau Bui D;Chen Y;Lin C.-Y;Lin T.-C.; Giau Bui D; Chen Y; Lin C.-Y; Lin T.-C.; YEH-NING CHEN |
| 臺大學術典藏 |
2021-08-31T05:35:44Z |
CEO overconfidence and bank loan contracting
|
Lin C.-Y;Chen Y;Ho P.-H;Yen J.-F.; Lin C.-Y; Chen Y; Ho P.-H; Yen J.-F.; YEH-NING CHEN |
| 臺大學術典藏 |
2021-08-31T02:35:27Z |
Combined intravenous immunoglobulin and baricitinib treatment for severe COVID-19 with rhabdomyolysis: A case report
|
Wu H.-Y.; CHIEN-TING PAN; Cheng C.-F.; Lin C.-Y.; Chang S.-N.; Chen Y.-C.; Wang C.-Y.; Chen Y.-F.; Chen C.-Y.; Ma M.H.-M.; Hwang J.-J. |
| 臺大學術典藏 |
2021-08-27T06:48:50Z |
Early Seroreversion After 2 Doses of Hepatitis A Vaccination in Human Immunodeficiency Virus–Positive Patients: Incidence and Associated Factors
|
Huang S.-H.; Huang C.-H.; Wang N.-C.; Chen T.-C.; Lee Y.-T.; Lin S.-P.; Lin T.-Y.; Lin C.-Y.; Lee Y.-L.; Lee C.-H.; Chen C.-P.; KUAN-YIN LIN; Chen G.-J.; Liu C.-E.; Cheng S.-H.; Lu P.-L.; Yang C.-J.; Hung C.-C.; on behalf of the Taiwan HIV Study Group |
| 臺大學術典藏 |
2021-08-27T06:48:46Z |
Dual therapy with dolutegravir plus boosted protease inhibitor as maintenance or salvage therapy in highly experienced people living with HIV
|
Lee Y.-L.; KUAN-YIN LIN; Cheng S.-H.; Lu P.-L.; Wang N.-C.; Ho M.-W.; Yang C.-J.; Liou B.-H.; Tang H.-J.; Huang S.-S.; Huang S.-H.; Chen T.-C.; Lin C.-Y.; Lin S.-P.; Lee Y.-T.; Hung C.-C.; Taiwan HIV Study Group |
